In 1997 the Netherlands established an infrastructure for influenza vaccination called the Dutch National Influenza Prevention Program (NPG). Aim is to protect people from illness and death due to influenza.
Because the influenza virus is continuously evolving, infection
does not confer the infected person with lifelong protection, as is
often the case with other infectious diseases. This is why there
are annual flu epidemics, and why the flu vaccine has to be adapted
every year and risk groups vaccinated every year. Vaccinated people
normally develop a protective amount of antibody within two to
three weeks.
On advice of the Dutch Health Council people at high risk for
complications of influenza are personally invited to see their
family doctor for a free of charge vaccination.
Target group
As of 2008, the target group of the NPG programme comprises:
persons aged 60 or over
children and adults with certain conditions, namely:
- patients with abnormalities and functional disorders of the
airways and lungs
- patients with a chronic heart disorder
- patients with diabetes mellitus
- patients with a chronic kidney disease
- patients who recently underwent a bone marrow transplant
- persons infected with HIV
- persons with a reduced resistance to infection (e.g. because of
(functional) asplenia, auto-immune disease, liver cirrhosis,
chemotherapy or immunosuppressive medication
children aged between 6 months and 18 years who are long-term
salicylate users
persons with a mental handicap living in residential homes
Share this page